Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Lilly Plans Mirikizumab Filing For Crohn’s After Phase III Success

Oct 12 2023

• By Joseph Haas

Lilly intends to go head-to-head with AbbVie's Skyrizi in IBD

Related Content

Lilly Unlucky? Lilly Leads Big Pharma In US FDA Complete Response Letters

May 26 2023

Lilly’s Latest Leadership Shuffle Gives CSO Skovronsky Immunology Oversight

Oct 04 2023

Lilly Strikes Out With The FDA For Second Time This Year With Mirikizumab CRL

Apr 14 2023

AbbVie’s Skyrizi Bests Stelara Head-To-Head In Crohn’s

Sep 12 2023

Lilly’s Mirikizumab Hits All Marks In First Phase III Study For UC

Mar 16 2021

Related Companies

Eli Lilly and Company

AbbVie Inc.

Johnson & Johnson

Additional Topics

Clinical Trials Business Strategies Biologics Research & Development Gastrointestinal BioPharmaceutical

More from Clinical Trials

More from R&D

Twitter feed RSS feed RSS feed

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window

Copyright © 2025 Pharma Intelligence UK Limited (Citeline), a Norstella company Pharma Intelligence UK Limited is a company registered in England and Wales with company number 13787459 whose registered.